Quantcast

Novel Drug Treatment Quickly Reverses Alzheimer’s Disease Resulting in a Significant Reduction in Assisted Living Expenses

April 17, 2013

Neurological Wellness Center Comments on Alzheimer´s Care Assisted Living Expenses Costing $90 to $200 Per Day According to a Recent Article in the Los Angeles Times*

(PRWEB) April 17, 2013

Implementing the treatment detailed in Perispinal etanercept: a new therapeutic paradigm in neurology by Dr. Tobinick can enable a severely impaired person needing full time assisted living care who is unable to recognize their own children or even count to ten to, after a single dose, recognize their children and count to ten with ease.** This restoration of memory and cognitive functions continues to build with a series of injections. “After three months of weekly injections, this individual may be able to regain the degree of independence and the lifestyle that they enjoyed up to three years earlier”, said Rolando Hernandez, M.D., neurosurgeon for Neurological Wellness Center.

In-home assisted living costs for Alzheimer´s patients average nearly $57,000 per year, according to a recent study by the Alzheimer´s Association. Medicare will not pay for assisted living or the cost of long-term care, according to Alzheimer´s Association vice president Beth Kallmyer.

The 12-week therapeutic treatment regimen that Neurological Wellness Center physician Rolando Hernandez, M.D., advises will cost about $800 per month for the prescription drugs. The good news is that drugs usually are included in Medicare plans. “Although there are a wide range of treatment outcomes, most people with Alzheimer´s will need just one dose every 10 to 14 days long term to maintain stable function. This will cost on a cash pay basis $450 to $625 per month,” said Dr. Hernandez.

The good news continues. The drug needed to facilitate this reversal of Alzheimer´s disease and enabling a life-changing recovery of memory and cognitive function is the widely-prescribed, heavily-advertised Amgen/Pfizer drug Enbrel. Enbrel is most commonly prescribed as a treatment for rheumatoid arthritis, an inflammatory disease of the joints. “Many of the impairments experienced by people with Alzheimer´s disease as well as stroke and traumatic brain injury are caused by excess inflammation in the brain. Once this excess inflammation is attenuated, the individual experiences a rapid recovery. This recovery extends to memory, mood, speech and physical function”, states Dr. Hernandez.

Why has mainstream media failed to report on this amazing breakthrough? “Actually they have but only to a limited extent. The TV show 60 Minutes ran an excellent piece featuring a remarkable recovery of an Australian man with Alzheimer´s in October 2011. This show has aired in Australia and New Zealand but not in the United States. I believe 60 Minutes´ parent, CBS, is beholden to their pharmaceutical advertisers whose extensively-advertised, minimally-effective, FDA-approved Alzheimer´s drugs would face strong competition from a drug that reverses the disease and facilitates a significant recovery”, said Dr. Hernandez. To watch this 60-minute segment titled “A New Shot At Life” on YouTube visit: video.au.msn.com/watch/video/a-new-shot-at-life/xa5v8hg.

For injections of Enbrel to be effective they must be administered to the soft fatty tissue in the back of the neck between cervical vertebrae C-5 and C-6. This simple subcutaneous injection, performed with a fine gauge ½ inch needle, is referred to as a perispinal injection. Neurological Wellness Center offers a complete two-hour course on Alzheimer’s treatment, stroke treatment and traumatic brain injury treatment covering all aspects of perispinal injection technique at their center in Managua Nicaragua.

For many, flying to Neurological Wellness Center in Managua Nicaragua to receive this personalized training is an enormous expense and inconvenience. To overcome this problem, Neurological Wellness Center, under the direction of Augusto Ramirez, M.D., created Perispinal Enbrel Step-By-Step Instructional Video and accompanying e-book. This 24-minute video and 37-page e-book are now available online at http://www.neurological-recovery-guide.com.

Augusto Ramirez, M.D., Director of Neurological Wellness Center, a private medical group in Managua Nicaragua, authorized this press release.

Neurological Wellness Center´s perispinal Enbrel is profoundly effective as an Alzheimer’s treatment, stroke treatment, [stroke clinical trial __title__ Neurological Recovery Guide] and as a TBI treatment. The complete treatment recommendation: for stroke is one 25mg injection of Enbrel every four days for a total of four doses over 16 days; for TBI is one 25mg injection of Enbrel every four days for a total of eight doses. This compares with Amgen/Pfizer´s FDA-approved dose schedule for moderate plaque psoriasis of 50mg twice weekly for three months followed by 50mg weekly for life. The Neurological Wellness Center´s maximum recommended dose for Alzheimer´s disease is 25mg/week for life.

The drug Enbrel is available now. Enbrel received FDA approval in 1998. Its safety profile is well understood. For Enbrel to effectively treat Alzheimer´s, stroke and TBI, it must be administered to the back of the neck precisely between the cervical vertebrae C-5 and C-6. This perispinal injection allows Enbrel to enter the brain by lymph drainage assisted by gravity. Fortunately for the millions of people now afflicted with Alzheimer´s, stroke and TBI, a video is now available online detailing in step-by-step fashion how to administer a perispinal injection of Enbrel,” said Dr. Rolando Rodrigues.

To enroll in a hands-on instructional course on perispinal injections visit http://www.reversealzheimersnow.com.

To purchase an instructional video and e-book on administering perispinal injections visit http://www.neurological-recovery-guide.com.

To purchase Enbrel at the lowest prices in North America visit http://www.genuine-enbrel-cheaper.com/.

**Study published in June 2010, by Edward Tobinick

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/4/prweb10534699.htm


Source: prweb



comments powered by Disqus